Abbott Laboratories (ABT) Long-Term Debt Repayments (2010 - 2026)

Abbott Laboratories has disclosed Long-Term Debt Repayments across 15 years of filings, most recently posting $1.4 billion for Q1 2026.

• Long-Term Debt Repayments for Q1 2026 came in at $1.4 billion, up 41.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 billion (up 185.9% YoY), and the FY2021 annual result was $48.0 million, down 96.4% from the prior year.
• Long-Term Debt Repayments came in at $1.4 billion for Q1 2026 at Abbott Laboratories, up from $501.0 million in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $1.4 billion in Q3 2023 to a low of $1.0 million in Q2 2022.
• The 5-year median for Long-Term Debt Repayments is $18.0 million (2024), against an average of $467.2 million.
• Across the five-year window, Long-Term Debt Repayments jumped 144400.0% in 2023 and sank 99.86% in 2024, its largest moves.
• Abbott Laboratories' Long-Term Debt Repayments stood at $1.0 million in 2022, then surged by 144400.0% to $1.4 billion in 2023, then tumbled by 99.86% to $2.0 million in 2024, then jumped by 24950.0% to $501.0 million in 2025, then surged by 182.63% to $1.4 billion in 2026.
• The last three Long-Term Debt Repayments figures came in at $1.4 billion (Q1 2026), $501.0 million (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.